



PATENT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant : Pastor et al.
Serial. No : 10/647,739 Examiner: Not Yet Assigned
Filed : August 25, 2003 Group Art Unit: 1632
For : THERAPY WITH CANNABINOID COMPOUNDS FOR THE
TREATMENT OF BRAIN TUMORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States
Postal Service as first class mail, in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-
1450

January 6, 2004
Date of Deposit
Bradley B. Geist
Attorney Name
[Signature]
Signature

27,551
PTO Registration No.
January 7, 2004
Date of Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449 and respectfully requests that the listed documents be considered by the Examiner and made of record in the above-captioned application. Unless otherwise indicated, a full text copy of each document is attached. The referenced citations are listed in the accompanying International Search Report and PTO Form 1449.


PATENT

Identification of the listed references in the PTO 1449 is not to be construed as an admission of the Applicant(s) or the attorneys of the Applicant(s) that such references are available as "prior art" against the subject application.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicant determines that the cited document(s) do not constitute "prior art" under United States law, applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

This statement is submitted more than 3 months from the application filing date but before the mailing date of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.98, submission of this Information Disclosure Statement requires no fee. However, the Commissioner is hereby authorized to charge the payment of any fees required in association with this communication to Deposit Account No. 02-4377.

Respectfully submitted,


By: Bradley B. Geist
Patent Office Reg. No. 27,551
30 Rockefeller Plaza
44th Floor
New York, NY 10112
(212) 408-2500
Attorneys for Applicant



Form PTO-1449 U.S. Department of Commerce
(REV. 2-82) Patent and Trademark Office

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.
A34700 PCT USA-I
(069277.0113)

Applicant
Pastor et al.

Filing Date
April 25, 2003

Group
1632

U.S. PATENT DOCUMENTS

*Exam. Init.										Document No.	Date	Name	Class	Subclass	Filing Date if Appro.

FOREIGN PATENT DOCUMENTS

										Document No.	Date	Country	Class	Subclass	<u>Translation</u> Yes No

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

			HARRIS, L.S., et al., "Retardation of tumor growth by Δ -9 tetrahydrocannabinol", The Pharmacologist (1974), vol. 16 (2), pag. 259.
			HARRIS, L.S., et al., "Anti-tumor properties of cannabinoids", Braude, M.C. & Stephen szara(ed) Pharmacology of marihuana", vol. 1 γ 2-A monograph of the National Institute of Drug Abuse. Proceedings of the Meeting Savannah, GA, USA. Dic. 3-6, 1974. Illus. Raven Press: New York, NY USA, ISBN 0-89004-067-2, 1976, pp.: 749-762.
			BAEK SEUNG-HWA, et al. "Synthesis and antitumor activity of cannabigerol", Archives of Pharmacol. Res. (Seoul), 1996, vol. 19 (3), pp.228-230.
			BAEK SEUNG-HWA, et al. "Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells", Archives of Pharmacol Res. (Seoul), June 1998, vol. 21(3), pp.353-356.
			RUIZ et al., " Δ -9 tetrahydrocannabinol induces apoptois in human prostate PC-3 cells via a receptor-independent mechanism", FEBS Lett. (1999), vol. 458 (3), pp.400-404, ISSN 0253-5823.

NY02:361207.1 Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.